Stemtech Corporation Reports Q2 2026 Financial Results with Improved Net Loss

Stemtech Corporation reported its financial results for the second quarter of 2026, revealing a net loss of $292,358, a slight improvement from the net loss of $296,280 recorded in the same period of 2025. For the first half of 2026, the company experienced a net loss of $1,453,418, compared to a loss of $1,755,006 in the prior year. The company's net sales for the three months ended June 30, 2026, were $629,312, down 9.8% from $697,925 in the same quarter of 2025. For the six-month period, net sales decreased by 30.2%, totaling $1,092,269 compared to $1,565,971 in 2025. The decline in revenue was attributed to constrained product availability, which limited the company's ability to fulfill distributor orders.

The company's cost of goods sold for the second quarter increased to $163,639 from $145,909 year-over-year, while gross profit fell to $465,673, resulting in a gross margin of 74.0%, down from 79.1% in the previous year. Operating expenses also decreased significantly, totaling $591,240 for the second quarter, down from $853,004 in 2025. This reduction was driven by lower commission expenses, which fell by nearly 60%, and a decrease in general and administrative costs. The operating loss for the quarter improved to $125,567 from $300,988 in the prior year.

In terms of operational metrics, Stemtech's current assets increased to $571,233 as of June 30, 2026, compared to $457,062 at the end of 2025, primarily due to a rise in inventory levels. However, current liabilities also rose to $11,112,964 from $10,587,013, resulting in a working capital deficit of $10,541,731. The company continues to face significant financial challenges, raising concerns about its ability to continue as a going concern. Management has indicated that it will require additional capital to meet its long-term operating requirements, primarily through equity or debt financing.

Strategically, Stemtech launched its e-commerce retail platform, Stemtech BioSciences, in February 2026, aiming to expand its distribution channels and increase direct consumer access to its products. The company is also focused on enhancing its Independent Business Partner (IBP) network, with plans to add 30,000 new representatives over the next 12 to 24 months. This initiative is expected to help stabilize sales and improve customer acquisition costs. Despite the current challenges, management remains optimistic about the potential for revenue growth and operational improvements in the future, contingent on restoring product availability and executing its strategic initiatives.